PGHL

P & G Health share price & financials

Price
₹6,244
Market cap
₹9.0k Cr
Sector
Healthcare
Calls analysed
2
Latest concall · Q4 FY26 · call held 18 Jun 2026

P & G Health Ltd Q4 FY26

Profit After Tax ₹327 cr +30%

What went well

  • Sales for FY26 reached close to ₹1400 crore, marking a 16% increase over the previous year.
  • Profit after tax for FY26 stood at ₹327 crores, demonstrating a 30% increase year-over-year.
  • Three new product innovations (Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream, Evion L5000) were successfully launched, contributing early-single digit points of growth to the overall business.
Read the full call →

What P & G Health Ltd does

Procter & Gamble Health Limited markets over-the-counter vitamin, mineral and supplement (VMS) branded products in India, targeting conditions such as neuropathy, vitamin-E deficiency, iron deficiency and nasal congestion. It earns by selling long-established brands — Neurobion, Evion, Livogen, Seven Seas, Polybion and Nasivion — through pharmacies, e-pharmacies and general retail, backed by outreach to healthcare professionals (HCPs). Manufacturing is outsourced to third-party contract manufacturers rather than run through owned plants, making it an asset-light branded consumer-healthcare business. The company also exports select brands to international markets including Nepal and Sri Lanka.

Segments

  • Consumer Healthcare (Vitamins, Minerals & Supplements)
Core consumer-healthcare brands
6 — Neurobion, Evion, Livogen, Seven Seas, Polybion, Nasivion
Manufacturing model
Asset-light — products sourced from third-party contract manufacturers; no owned manufacturing plants
Distribution channels
Pharmacies, e-pharmacies and traditional/general retail, with direct outreach to healthcare professionals (HCPs)
Export presence
Sells in international markets including Nepal and Sri Lanka
Community health footprint
Mobile Healthcare Units deployed across 8 states (last-mile health access program)
Category focus
Vitamins, Minerals & Supplements (VMS) — India's OTC preventive-health category
Headquarters Mumbai, Maharashtra Company website

Guidance record · Q4 FY26

what the last two calls moved 5 tracked 3 delivered 0 missed 2 open
  • Rural and E-commerce Coverage delivered said Q4 FY25 Promised: Increase coverage in Rural Areas and leverage e-commerce to broaden availability of the portfolio. Q4 FY26: Added nearly 30,000 pharmacies and HCPs in extra-urban geographies. New launch Livogen Iron Gummies ranked #1 with highest market share among iron gummies on Amazon.
  • New Product Contribution to Growth open said Q4 FY26 Promised: Ensure new product launches (Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream, Evion L5000) continue or increase their contribution to growth from the current early-single digit points. Q4 FY26: New launches have collectively contributed early-single digit points of growth to the overall business this year, exceeding expectations.

All 5 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 7.4%, net profit up 45.5% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue313 310 311 339 325 +4%374 +21%370 +19%364 +7%
EBITDA114 123 81 90 120 +5%110 −11%136 +68%100 +11%
Net profit82 91 61 66 89 +9%78 −14%95 +56%96 +45%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −14.5% 1Y

₹5.0k₹5.5k₹6.0k₹6.5k₹7.0kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q4 FY26 — 18 Jun 2026

1Y: ₹6,329.5 on 10 Sept 2025 → ₹5,411.5. High ₹6,918.5 (14 Jul 2026), low ₹4,778.6 (2 Apr 2026).

How the price took the results

close before → close after

Q4 FY26
+1.0%
18 Jun

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 5.2% a year over 3 years, FY23 to FY26. Operating margin widened to 32.5%.

Year endingFY23FY24FY25FY26
Revenue₹1.2k Cr₹1.2k Cr₹1.3k Cr₹1.4k Cr
Operating profit₹325 Cr₹306 Cr₹408 Cr₹466 Cr
Operating margin26.4%26.6%32.1%32.5%
Interest₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Depreciation₹27 Cr₹27 Cr₹22 Cr₹24 Cr
Net profit₹230 Cr₹202 Cr₹300 Cr₹358 Cr
Net margin18.7%17.5%23.6%25.0%
Cash from operations₹236 Cr₹228 Cr₹169 Cr₹338 Cr
Free cash flow₹198 Cr₹207 Cr₹168 Cr₹323 Cr
ROCE45.0%45.0%48.0%84.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹17 Cr₹17 Cr₹17 Cr₹17 Cr₹17 Cr₹17 Cr
Reserves₹687 Cr₹600 Cr₹734 Cr₹522 Cr₹603 Cr₹508 Cr
Borrowings₹8 Cr₹3 Cr₹12 Cr₹10 Cr₹6 Cr₹9 Cr
Other liabilities₹275 Cr₹269 Cr₹338 Cr₹247 Cr₹268 Cr₹308 Cr
Total liabilities₹986 Cr₹888 Cr₹1.1k Cr₹794 Cr₹894 Cr₹841 Cr
Fixed assets₹104 Cr₹112 Cr₹144 Cr₹128 Cr₹106 Cr₹102 Cr
Capital work in progress₹39 Cr₹41 Cr₹32 Cr₹6 Cr₹13 Cr₹14 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹843 Cr₹736 Cr₹925 Cr₹660 Cr₹776 Cr₹726 Cr
Total assets₹986 Cr₹888 Cr₹1.1k Cr₹794 Cr₹894 Cr₹841 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public added +2.38 pp while DIIs trimmed −1.71 pp. The shareholder count shrank 7% to 49,056.

Promoters
51.8%
FIIs
6.3%
DIIs
12.4%
Public
29.4%

Since Jun 2025

  • Public +2.38 pp
  • DIIs −1.71 pp
  • FIIs −0.66 pp

How it drifted, 12 quarters

Over this window FIIs fell from 7.4% to 6.3% — −1.1 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 51.8%, FIIs 7.4%, DIIs 12.3%, Public 28.5%.Dec '23: Promoters 51.8%, FIIs 7.6%, DIIs 12.7%, Public 27.9%.Mar '24: Promoters 51.8%, FIIs 6.2%, DIIs 13.7%, Public 28.2%.Jun '24: Promoters 51.8%, FIIs 6.4%, DIIs 14.6%, Public 27.2%.Sep '24: Promoters 51.8%, FIIs 6.6%, DIIs 14.8%, Public 26.7%.Dec '24: Promoters 51.8%, FIIs 7.0%, DIIs 14.7%, Public 26.5%.Mar '25: Promoters 51.8%, FIIs 6.9%, DIIs 14.2%, Public 27.1%.Jun '25: Promoters 51.8%, FIIs 7.0%, DIIs 14.2%, Public 27.0%.Sep '25: Promoters 51.8%, FIIs 7.2%, DIIs 13.9%, Public 27.1%.Dec '25: Promoters 51.8%, FIIs 7.0%, DIIs 13.8%, Public 27.4%.Mar '26: Promoters 51.8%, FIIs 6.2%, DIIs 13.7%, Public 28.3%.Jun '26: Promoters 51.8%, FIIs 6.3%, DIIs 12.4%, Public 29.4%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of P & G Health Ltd above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Procter And Gamble Overseas India B.V. 51.82%unchanged
Nippon Life India Trustee Ltd-A/C Nippon India Mul Mutual fund4.18%unchanged
Life Insurance Corporation Of India Insurer1.91%unchanged
UTI-Mnc Fund Mutual fund1.69%−0.09 pp
Aditya Birla Sun Life Trustee Private Limited A/C Mutual fund1.22%newly disclosed
Procter & Gamble Asia Pte. Ltd. 0.00%unchanged
Procter & Gamble Australia Proprietary Limited 0.00%unchanged
Procter & Gamble Azerbaijan Services LLC 0.00%unchanged
Procter & Gamble Bangladesh Private Ltd. 0.00%unchanged
Procter & Gamble Blois S.A.S. 0.00%unchanged
Procter & Gamble Brazil Holdings B.V. 0.00%unchanged
Procter & Gamble Bulgaria EOOD 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in PGHL

Filings to Aug 2026

0 new, 0 added, 0 trimmed, 0 sold out — net +0.00 L shares (+0.0%).

Held by funds
₹401 Cr
1 schemes
Biggest holder
Nippon India Small Cap Fund
₹401 Cr · 0.5% of that fund
SchemeHoldingLast month
Nippon India Small Cap Fund Nippon India Mutual Fund₹401 Crheld

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Aug 2026

0 added, 0 trimmed — net 0 shares (+0.0%)

Funds are sitting on
+32%
vs est. average cost
Held by funds
₹401 Cr
1 schemes · ≈ 4.8% of the company

Shares held by these funds −26%

Aug '23 6.95 L shares Jul '26

What the price assumes

Expensive

To justify its price of ₹5412, this stock must grow earnings at 19% every year for 7 years. Our analysis caps realistic growth at ~11%. At that growth it is worth ₹3489 — downside of 36%.

Growth the price implies
19.1% a year
for 7 years, fading to 4%
It has actually compounded at
10.8% a year
net profit, FY23–FY26 · EPS 10.7%
The gap
0.1 pp
-36% downside if it only repeats history
Price today ₹5,411.5 Value at the reference growth ₹3,489.46

Change the assumptions yourself →

All earnings calls (2)

Read the Q4 FY26 call →

Learn to analyse P & G Health Ltd

Guides on how to read this kind of business and the numbers that matter.